Samantha Polly, MD
Dermatology · Cleveland, OHNPI 1336676618
Payments from drug & device makers
What this record shows
This record is dominated by grants: $80,000 of the $80,467 with a category attached, or 99.4%. Pfizer accounts for 99.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $80,041 and has fallen 99.9% since, to $62 in 2024. Among dermatology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $6189.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$80K
- AbbVie$140
- E.r. Squibb & Sons, L.L.C.$123
- Sun Pharmaceutical Industries Inc.$62
- Johnson & Johnson$45
- Bristol Myers Squibb$43
- plus $54 from 2 others
What the payments were for
- Grants$80,00099%
- Food & beverage$4671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 2 | $80,000 |
| AbbVie | 4 | $140 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Sun Pharmaceutical Industries Inc. | 1 | $62 |
| Johnson & Johnson | 1 | $45 |
| Bristol Myers Squibb | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $41 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$80,467 in reported general payments places this provider in the 90th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 17 | $82,350 |
| Enbrel SureclickEtanercept | 11 | $80,988 |
| Dupixent SyringeDupilumab | 12 | $48,899 |
| Fluorouracil | 77 | $5,198 |
| Clobetasol Propionate | 52 | $2,363 |
| Fluocinolone Acetonide | 19 | $1,196 |
| Tretinoin | 13 | $1,000 |
| Clindamycin Phosphate | 33 | $950 |
| Ketoconazole | 83 | $945 |
| Triamcinolone Acetonide | 75 | $907 |
| Metronidazole | 15 | $688 |
| Doxycycline Monohydrate | 22 | $465 |
| Econazole Nitrate | 16 | $438 |
| Hydrocortisone | 21 | $308 |
| Hydroxychloroquine Sulfate | 12 | $287 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Cleveland
- Neil KormanCleveland$824K
- Shilpi KhetarpalCleveland$383K
- Anthony FernandezCleveland$352K
- Alex HirshCleveland$159K
- Mara Weinstein VelezCleveland$96K
- Wilma BergfeldCleveland$35K
- David HamrockCleveland$19K
- Matthew ZirwasBexley$3.3M
- George DrewMarion$1.9M
- Rocco SerraoDayton$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.